FDA Approval for SCM Following BTGS Drug Approval
SCM Pharma’s UK-based clinical development and manufacturing facility has been approved at the first attempt by FDA.
The inspection at the contract development and manufacturing organisation (CDMO) was triggered by the company supporting British specialist healthcare company BTG in preparation for the commercial launch of Varithena (polidocanol injectable foam), after providing clinical development consultancy for the product for several years.
FDA has now approved BTG’s varicose veins treatment (previously known as Varisolve PEM), which uses an injectable, pharmaceutical-grade foam to dissolve the veins as an alternative to surgical removal.
This gives the CDMO’s Prudhoe site the official thumbs up from US regulators following an inspection in November after it was named on the New Drug Application (NDA) as a one of the commercial suppliers for the product.
SCM Pharma has worked with BTG since 2005, assisting with process development, sterile manufacturing, packaging and distribution to support clinical trial studies in the US. It specialises in the sterile production of products for clinical trials and the supply of licensed drugs in niche commercial markets. It recently opened the doors of a new $10-million site, which complements its now FDA-approved clinical manufacturing facility nearby.
Dianne Sharp, managing director at SCM Pharma, said: “The FDA approval at our headquarters in Prudhoe tops off a milestone year for our business after gaining our MHRA licence for our new commercial manufacturing facility in Newburn in the summer.
“As we move into our tenth year in business, this approval represents another major project where we have played a major developmental and production role to take a client with a complex product from early phase trials to commercial. This is something I am extremely proud of and is testament to our brilliant technical, quality and production teams.
“We will be looking to immediately strengthen our US team and presence as this approval will no doubt trigger more demand for our small scale clinical and contract manufacturing services in North America,” added Dianne.
The award-winning CDMO already works with several companies in the US and has built its reputation around the sterile filling of novel products, difficult processes and applications and dangerous substances such as potent products requiring high containment.
The news is a much-needed boost to the global sterile production market following the issuing of many warning letters by FDA, the closure of other sites and supply shortages due to production being halted at some CMO facilities.
Independently owned, most of SCM Pharma’s clients’ projects involve the aseptic filling and terminal sterilisation of liquids and powders into vials, ampoules and syringes.
In a bold move, the CDMO recently used CPHI in Frankfurt as a platform to offer pharmaceutical companies across the world the opportunity to design their clinical and contract manufacturing projects from a ‘blank canvas’ of cleanroom space.
In contrast to contract manufacturers, SCM Pharma is inviting drug developers and licensed product owners the opportunity to utilise dedicated space at its new site to design a process around their specific product manufacturing needs.
The latest appointments and promotions across the pharmaceutical supply chain.
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers?
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government.
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance